Citation Impact
Citing Papers
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
2011 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein
2000 StandoutNobel
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 StandoutNatureNobel
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
2011
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
The von Hippel–Lindau tumour suppressor protein: new perspectives
1999 StandoutNobel
Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
1998
Comparative Sequence Analysis of the VHL Tumor Suppressor Gene
2000
Recombinant Adenovirus Expressing Von Hippel-Lindau-Mediated Cell Cycle Arrest Is Associated with the Induction of Cyclin-Dependent Kinase Inhibitor p27Kip1
1998
Cdc53 is a scaffold protein for multiple Cdc34/Skp1/F-box protein complexes that regulate cell division and methionine biosynthesis in yeast
1998
Analysis of von Hippel—Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity
2002
C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation
2001 StandoutNobel
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
2002
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
1999
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
The pressure rises: update on the genetics of phaeochromocytoma
2002
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
2000
A Complex of Cdc4p, Skp1p, and Cdc53p/Cullin Catalyzes Ubiquitination of the Phosphorylated CDK Inhibitor Sic1p
1997
The ubiquitin-proteasome proteolytic pathway
1994 StandoutNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2
2000
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
2001
The von Hippel–Lindau tumor suppressor protein
2001 StandoutNobel
Ubiquitination of a Novel Deubiquitinating Enzyme Requires Direct Binding to von Hippel-Lindau Tumor Suppressor Protein
2002
The Hallmarks of Cancer
2000 Standout
von Hippel-Lindau Disease
1997 StandoutNobel
F-Box Proteins Are Receptors that Recruit Phosphorylated Substrates to the SCF Ubiquitin-Ligase Complex
1997
HIF-1, O2, and the 3 PHDs
2001 StandoutNobel
Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC
1999
A protein conjugation system essential for autophagy
1998 StandoutNatureNobel
The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix
1998 StandoutNobel
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
2001
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
Ubiquitin-dependent regulation of COPII coat size and function
2012 StandoutNatureNobel
von Hippel-Lindau disease
2003 Standout
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
1998 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
BTB/POZ Domain Proteins Are Putative Substrate Adaptors for Cullin 3 Ubiquitin Ligases
2003
The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C
2001
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Renal-Cell Carcinoma
2005
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways
1997
Mobility of the von Hippel–Lindau tumour suppressor protein is regulated by kinesin-2
2008
Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
2001
Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity
1999
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
2002
Modification of yeast Cdc53p by the ubiquitin-related protein Rub1p affects function of the SCFCdc4 complex
1998
VHL, the story of a tumour suppressor gene
2014
HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells
2007 StandoutNobel
Formation of the VHL–Elongin BC Tumor Suppressor Complex Is Mediated by the Chaperonin TRiC
1999
Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor
2003
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex
2004 StandoutNatureNobel
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressor
2002
The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity
2003
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
2003
Focus on kidney cancer
2004
A ubiquitin-like system mediates protein lipidation
2000 StandoutNatureNobel
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
1999
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease
2000
Software and database for the analysis of mutations in the VHL gene
1998
An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells
2002 StandoutNobel
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
1999
Degradation of Proteins with Acetylated Amino Termini by the Ubiquitin System
1989 StandoutScienceNobel
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
1999
β-Arrestin–Mediated Localization of Smoothened to the Primary Cilium
2008 StandoutScienceNobel
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
2000
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
2000
Regulation of Receptor Fate by Ubiquitination of Activated β 2 -Adrenergic Receptor and β-Arrestin
2001 StandoutScienceNobel
Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein
1998
Protective Function of von Hippel-Lindau Protein against Impaired Protein Processing in Renal Carcinoma Cells
1999
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
SCF and Cullin/RING H2-Based Ubiquitin Ligases
1999
PROLINE HYDROXYLATION AND GENE EXPRESSION
2005 StandoutNobel
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products
2000
The von Hippel-Lindau Tumor Suppressor Gene
2020
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein
1999
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
1998
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
1997
Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss
2010 StandoutScienceNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
1998
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
2001
Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.
2002
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
2002
Factors regulating the transcriptional elongation activity of RNA polymerase II
1998
von Hippel–Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination
2003
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
Structural Basis of Transcription: RNA Polymerase II at 2.8 Ångstrom Resolution
2001 StandoutScienceNobel
VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling
2001
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in Mice
2005
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Whose end is destruction: cell division and the anaphase-promoting complex
1999
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity
2002 StandoutNobel
De novo design of protein logic gates
2020 StandoutScienceNobel
Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
1999
Works of Robert Worrell being referenced
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
2009 StandoutNobel
Molecular cytogenetic characterization of early and late renal cell carcinomas in Von Hippel‐Lindau disease
2001
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
1997
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor
2003